Advertisement

Lung

, Volume 168, Supplement 1, pp 445–453 | Cite as

The use of transdermal nicotine in smoking cessation

  • Ph. Müller
  • Th. Abelin
  • R. Ehrsam
  • P. Imhof
  • H. Howald
  • D. Mauli
Smoke-Free Europe In The Year 2000

Abstract

The transdermal administration of nicotine by means of a transdermal nicotine system (TNS) affords a novel way of nicotine replacement to alleviate smoking cessation. The plasma levels of nicotine maintained with the TNS are in the range of the footpoint concentrations observed in smokers. The efficacy of the TNS was investigated in two placebo-controlled double-blind smoking cessation programs with minimal contact and minimal psychological support. A total of 311 smokers were treated for 3 months or 9 weeks. The abstinence rates at the end of the treatment and weaning periods were almost doubled in the TNS groups (36% and 39%) as compared to the placebo groups (23% and 20%) with a significant difference for both studies (p<0.05). These data suggest that the TNS can also improve the smoking cessation rates under the conditions of general medical advice, making it suitable for use outside of specialized smoking cessation centers.

Key words

Transdermal administration of nicotine Smoking cessation Minimal psychological support Weaning periods Abstinence rates 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    U.S. Department of Health Office on Smoking (1988) The Health Consequences of Smoking: Nicotine Addiction. A report of the Surgeon General, 1988. U.S. Government Printing Office, Washington, DC, p 2040Google Scholar
  2. 2.
    Russell, MAH, Jarvis MJ (1985) Theoretical background and clinical use of nicotine chewing gum. National Institute on Drug Abuse. Res Monogr 53:110–130Google Scholar
  3. 3.
    Dubois JP, Sioufi A, Müller Ph, Mauli D, Imhof PR (1989) Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Methods Findings Exp Clin Pharmacol 11:187–195Google Scholar
  4. 4.
    Müller Ph, Imhof PR, Mauli D, Milovanovic D (1989) Human pharmacological investigations of a transdermal nicotine system. Methods Findings Exp Clin Pharmacol 11:197–204Google Scholar
  5. 5.
    Müller Ph, Schlösser R, Imhof P, Dubach UC, Sioufi A (1988) Haemodynamic and humoral effects of cigarette smoking. In: Aoki M, Hisamichi S, Tominaga S (eds) Smoking and health 1987. Excerpta Medica, Elsevier Science Publishers, Amsterdam—New York—Oxford, 739–741Google Scholar
  6. 6.
    Sioufi A, Parisot C, Sandrenan N, Dubois JP (1989) High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. Methods Findings Exp Clin Pharmacol 11:179–185Google Scholar
  7. 7.
    Abelin T, Bühler A, Müller P, Vesanen K, Imhof PR (1989) Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet I:7–10CrossRefGoogle Scholar
  8. 8.
    Abelin TH, Ehrsam R, Bühler-Reichert A, Imhof PR, Müller Ph, Thommen A, Vesanen K (1989) Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Findings Exp Clin Pharmacol 11:205–214Google Scholar
  9. 9.
    Fagerström K-O (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235–241PubMedCrossRefGoogle Scholar
  10. 10.
    West R, Schneider N (1987) Craving for cigarettes. Br J Addict 82:407–415PubMedCrossRefGoogle Scholar
  11. 11.
    Research Committee of the British Thoracic Society (1983) Comparison of four methods of smoking withdrawal in patients with smoking-related diseases. Br Med J 286:595–597CrossRefGoogle Scholar
  12. 12.
    Lam W, Sze PC, Sacks HS, Chalmers TC (1987) Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet II:27–30CrossRefGoogle Scholar
  13. 13.
    Russell MAH, Merriman R, Stapleton J, Taylor W (1983) Effect of nicotine chewing gum as an adjunct to general practitioners’ advice against smoking. Br Med J 287:1782–1785CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc 1990

Authors and Affiliations

  • Ph. Müller
    • 1
  • Th. Abelin
    • 2
  • R. Ehrsam
    • 3
  • P. Imhof
    • 1
  • H. Howald
    • 1
  • D. Mauli
    • 1
  1. 1.Clinical Pharmacology, Pharmaceutical DivisionCIBA-GEIGY Ltd.Basle
  2. 2.Department of Preventive MedicineUniversity of BerneSwitzerland
  3. 3.Department of Physical EducationUniversity of BasleSwitzerland

Personalised recommendations